ArticleJournal of food and drug analysis2026
The protective potential of intestinal Bifidobacterium-derived extracellular vesicles with unique lipid composition against blue light-induced damage in retinal cells.
Article in Journal of food and drug analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bifidobacterium longum is a probiotic that resides in the intestine, and extracellular vesicles (EVs) released by microorganisms have garnered attention in recent years for their role in regulating host health. This study found that triacylglycerol, cholesteryl esters, and free fatty acid (18:0 and 16:0) are primarily composed of lipids in B. longum-derived EVs by lipidomics assay. Such lipid composition facilitates the entry of EVs into ARPE-19 cells and protects the cells from oxidative death induced by blue light exposure. Transcriptomic analysis revealed that treatment with B. longum-derived EVs can regulate phosphoinositide 3-kinase and mTOR, thereby enhancing the survival capacity of blue light-induced ARPE-19 cells. Intestinal microbiota is strongly associated with host disease, and this study provides a strategy suggesting that intestinal probiotic EVs might potentially be used in the future to protect eyes from damage caused by blue light sensitivity through the gut-eye axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.